- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05487794
Effect of Dose Fractionation of Testosterone Cypionate on Transgender Men With Erythrocytosis
May 8, 2023 updated by: SERGIO HENRIQUE PIRES OKANO, University of Sao Paulo
Effect of Dose Fractionation of Testosterone Cypionate on Hematocrit in Transgender Men With Erythrocytosis Secondary to Testosterone Use.
A transgender man is someone with a male identity who were born with a vulva and vagina.
The acquisition of masculine characters can come from surgery or from the use of testosterone.
Despite the benefit of using this hormone in relation to hair development, muscle mass gain and changes in voice timbre, its use can cause an increase in the hematocrit (Ht) level.
When erythrocytosis occurs (Ht ≥ 50%), the currently proposed conduct is the suspension of cross-hormonization for 3 months, which has negative effects on the affirmation process.
This project aims to assess whether reducing the dose of testosterone cypionate by half (100mg/15d) can mitigate the negative outcomes caused by the suspension with the benefit of reducing the hematocrit level in trans patients who developed erythrocytosis using testosterone.
This is a pilot study that will compare the intervention (testosterone cypionate 100 mg, fortnightly) to the suspension of the drug, both for 3 months, with the main outcome being the hematocrit level.
Hormonal and biochemical levels and the Hospital Anxiety and Depression scale (HAD) will also be evaluated in patients treated at the Gender Incongruence Outpatient Clinic of the Hospital das Clínicas of the Faculty of Medicine of Ribeirão Preto.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: SERGIO HENRIQUE PIRES OKANO, MSC
- Phone Number: 16996136856
- Email: SERGIO.OKANO@USP.BR
Study Locations
-
-
SP
-
Ribeirão Preto, SP, Brazil
- Recruiting
- Faculdade de Medicina de Ribeirão Preto - FMRP-USP
-
Contact:
- Lucia Lara, Professor
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 38 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- TM aged between 18 and 40 years in threatmeant with Testosterone Cypionate 200mg/2mL with a diagnosis of erythrocytosis (Ht⩾50%).
Exclusion Criteria:
- TM with polycythemia vera or secondary to other pathologies (chronic kidney disease, severe lung disease, chronic myeloid leukemia, lymphoma, liver diseases and Cushing's syndrome);
- TM in use of hormonal contraceptives or copper IUDs;
- TM with psychiatric conditions such as severe psychotic disorders, severe personality disorders
- Patients with Ht > 54.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1 (T100)
|
Testosterone is also responsible for increasing hematocrit by stimulating erythropoiesis (Velho et al., 2017).
In cisgender men, who are hypogonadal and do not adequately produce testosterone, treatment with the use of testosterone is associated with stimulation of erythropoiesis, which can potentially increase blood viscosity, resulting in secondary erythrocytosis (Hajjar et al., 1997).
|
No Intervention: Group 1 (T0)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Erythrocytosis
Time Frame: 3 months
|
To evaluate if the reduction of the dose of Testosterone Cypionate 200 mg to 100 mgm, biweekly, is effective to normalize the hematocrit in TM with erythrocytosis.
Hemoglobin and hematocrit: will be measured by automated counting in the Biochemistry laboratory of the HCRP, using the Siemens Advia 2120i device (Siemens Healthcare GmbH®, Munich, Germany).
Blood collection will be carried out in Recrututo and 3 months after intervention or control.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efects on lipids and glucose levels
Time Frame: 3 monsths. Blood collection will be carried out in recruitment and 3 months after intervention or control.
|
Blood samples will be collected between seven and eight in the morning, after a minimum of twelve hours fasting.
In each evaluation, 20 mL of whole blood will be collected and stored in conical plastic tubes (BD-Becton Dickinson, Plymouth, United Kingdom) with a vacuum and a separating gel barrier.
It will be measured: total cholesterol (TC), HDL-cholesterol and triglycerides (TG) by enzymatic method in the Biochemistry laboratory of HCRP.
The device used will be the Siemens Atellica CH 930 (Siemens Healthcare GmbH®, Munich, Germany).
LDL-cholesterol will be calculated from the Friedewald formula, if there is no dosage of TG greater than 400mg/dL (Friedewald et al., 1972).
Fasting blood glucose will be determined by the enzymatic method in the Biochemistry laboratory of the HCRP and the device used will be the Siemens Atellica CH 930 (Siemens Healthcare GmbH®, Munich, Germany)
|
3 monsths. Blood collection will be carried out in recruitment and 3 months after intervention or control.
|
Anxiety and Depression Hospital Scale (HAD)
Time Frame: The scale will be applied in recruitment and 3 months after intervention or control.
|
To evaluate the emotional state regarding the presence of anxiety and depression, the Brazilian version of the Hospital Anxiety and Depression Scale (HAD) will be used, which consists of 14 questions that assess some aspects of mood and behavior (Appendix 4).
Scores ≥ 9 in the questions corresponding to anxiety or depression characterizes the psychic state of the woman.Zigmond & Snaith, 1983).
|
The scale will be applied in recruitment and 3 months after intervention or control.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2022
Primary Completion (Anticipated)
January 31, 2025
Study Completion (Anticipated)
July 31, 2025
Study Registration Dates
First Submitted
July 26, 2022
First Submitted That Met QC Criteria
August 1, 2022
First Posted (Actual)
August 4, 2022
Study Record Updates
Last Update Posted (Actual)
May 9, 2023
Last Update Submitted That Met QC Criteria
May 8, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Hematologic Diseases
- Polycythemia
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Androgens
- Anabolic Agents
- Testosterone
- Methyltestosterone
- Testosterone undecanoate
- Testosterone enanthate
- Testosterone 17 beta-cypionate
Other Study ID Numbers
- DGO-777
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Diseases
-
St. Jude Children's Research HospitalRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
University of Colorado, DenverNot yet recruitingHematologic Malignancy | Pediatric Patients | Other Hematologic ConditionUnited States
-
Epizyme, Inc.WithdrawnRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingHematologic MalignancyChina
-
Innovent Biologics (Suzhou) Co. Ltd.Recruiting
-
Massachusetts General HospitalRecruiting
-
Fondazione EMN Italy OnlusCompletedHEMATOLOGIC MALIGNANCIESItaly
-
Center for International Blood and Marrow Transplant...National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedHematologic MalignancyUnited States
-
Rigshospitalet, DenmarkNovo Nordisk A/SCompletedHematologic MalignancyDenmark
-
SecuraBioCompletedHematologic MalignancyUnited States, Italy
Clinical Trials on Testosterone Cypionate 100 MG/ML
-
Dana-Farber Cancer InstituteNational Institute on Aging (NIA)RecruitingProstate CancerUnited States
-
St Vincent's Hospital, SydneyRecruitingCastration-resistant Prostate Cancer | Homologous Recombination DeficiencyAustralia
-
The University of Texas Medical Branch, GalvestonNational Cancer Institute (NCI)CompletedCachexia | Squamous Cell CarcinomaUnited States
-
University of MiamiAcerus Pharmaceuticals CorporationCompletedHypogonadism, MaleUnited States
-
University of Sao Paulo General HospitalNot yet recruitingMenopause | Testosterone Deficiency | Estrogen Deficiency
-
University of California, Los AngelesNational Multiple Sclerosis SocietyCompleted
-
University of Colorado, DenverCompletedKlinefelter SyndromeUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Clarus TherapeuticsRecruitingProstate Cancer | Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Antares Pharma Inc.Completed